168 related articles for article (PubMed ID: 19451340)
1. Favourable use of non-boosted fosamprenavir in patients treated with warfarin.
Honda H; Gatanaga H; Matsumura J; Kamimura M; Goto K; Tsukada K; Honda M; Teruya K; Kikuchi Y; Oka S
Int J STD AIDS; 2009 Jun; 20(6):441. PubMed ID: 19451340
[No Abstract] [Full Text] [Related]
2. Anti-HIV agents. Saquinavir with fosamprenavir.
TreatmentUpdate; 2004; 16(3):9. PubMed ID: 17219609
[No Abstract] [Full Text] [Related]
3. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
Molina JM; Ait-Khaled M; Rinaldi R; Penco G; Baril JG; Cauda R; Soriano V; Pialoux G; Wire MB; Lou Y; Givens N; Craig C; Nichols WG; Barbosa I; Yeo J;
J Antimicrob Chemother; 2009 Aug; 64(2):398-410. PubMed ID: 19515730
[TBL] [Abstract][Full Text] [Related]
4. Fosamprenavir calcium plus ritonavir for HIV infection.
Torres HA; Arduino RC
Expert Rev Anti Infect Ther; 2007 Jun; 5(3):349-63. PubMed ID: 17547501
[TBL] [Abstract][Full Text] [Related]
5. Comment on: Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis.
Lanzafame M; Lattuada E; Corsini F
J Antimicrob Chemother; 2009 Jul; 64(1):215-6; author reply 216. PubMed ID: 19318364
[No Abstract] [Full Text] [Related]
6. Lower dose of ritonavir approved for use with fosamprenavir.
Sax PE
AIDS Clin Care; 2007 Dec; 19(12):106. PubMed ID: 18399004
[No Abstract] [Full Text] [Related]
7. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
[TBL] [Abstract][Full Text] [Related]
8. Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials.
Marcelin AG; Flandre P; Molina JM; Katlama C; Yeni P; Raffi F; Antoun Z; Ait-Khaled M; Calvez V
Antimicrob Agents Chemother; 2008 Dec; 52(12):4251-7. PubMed ID: 18852278
[TBL] [Abstract][Full Text] [Related]
9. Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavir.
Masquelier B; Assoumou KL; Descamps D; Bocket L; Cottalorda J; Ruffault A; Marcelin AG; Morand-Joubert L; Tamalet C; Charpentier C; Peytavin G; Antoun Z; Brun-Vézinet F; Costagliola D;
J Antimicrob Chemother; 2008 Jun; 61(6):1362-8. PubMed ID: 18390885
[TBL] [Abstract][Full Text] [Related]
10. Fosamprenavir: a new PI option. Interview by Craig Sterritt.
Nadler J
IAPAC Mon; 2004 Feb; 10(2):50-2. PubMed ID: 15106520
[No Abstract] [Full Text] [Related]
11. Fosamprenavir: drug development for adherence.
Hester EK; Chandler HV; Sims KM
Ann Pharmacother; 2006; 40(7-8):1301-10. PubMed ID: 16757678
[TBL] [Abstract][Full Text] [Related]
12. Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment.
Seminari E; De Bona A; Gentilini G; Galli L; Schira G; Gianotti N; Uberti-Foppa C; Soldarini A; Dorigatti F; Lazzarin A; Castagna A
J Antimicrob Chemother; 2007 Oct; 60(4):831-6. PubMed ID: 17684056
[TBL] [Abstract][Full Text] [Related]
13. [FPV plus SQV plus a mini-dose ritonavir. "Double boosting with compatible partners].
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():92-3. PubMed ID: 15373070
[No Abstract] [Full Text] [Related]
14. Safety and efficacy of fosamprenavir in human immunodeficiency virus-infected pregnant women.
Martorell C; Theroux E; Bermudez A; Garb J; Kronschnabel D; Oie K
Pediatr Infect Dis J; 2010 Oct; 29(10):985. PubMed ID: 20859183
[No Abstract] [Full Text] [Related]
15. Four posters add to our knowledge of Lexiva.
Proj Inf Perspect; 2008 Dec; (47):7-8. PubMed ID: 19227558
[No Abstract] [Full Text] [Related]
16. Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis.
Gatti F; Nasta P; Loregian A; Puoti M; Matti A; Pagni S; de Requena DG; Prestini K; Parisi SG; Bonora S; Palù G; Carosi G
J Antimicrob Chemother; 2009 Mar; 63(3):575-8. PubMed ID: 19151039
[TBL] [Abstract][Full Text] [Related]
17. Fosamprenavir (GW433908)/ritonavir in HIV-infected patients: efficacy and safety results from the Spanish Expanded Access Program.
Pérez-Elias MJ; Sánchez-Conde M; Soriano V; Mallolas J; Luque I; Rodríguez-Alcántara F;
Enferm Infecc Microbiol Clin; 2009 Jan; 27(1):28-32. PubMed ID: 19218000
[TBL] [Abstract][Full Text] [Related]
18. Viral response in stable patients switching to fosamprenavir/ritonavir monotherapy (the FONT Study).
Saumoy M; Tiraboschi J; Gutierrez M; Niubó J; Domingo P; Vila A; Podzamczer D
HIV Med; 2011 Aug; 12(7):438-41. PubMed ID: 21729229
[TBL] [Abstract][Full Text] [Related]
19. FDA notifications. FDA approves NDA for Lexiva.
AIDS Alert; 2007 Dec; 22(12):142. PubMed ID: 18415960
[No Abstract] [Full Text] [Related]
20. [Maintaining independence. New protease inhibitor receives drug approval recommendation].
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():84-5. PubMed ID: 15373062
[No Abstract] [Full Text] [Related]
[Next] [New Search]
